Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Arachidonate 5-lipoxygenase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | ko:K00461 arachidonate 5-lipoxygenase [EC1.13.11.34], putative | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma japonicum | IPR001024,Lipoxygenase, LH2;IPR013819,Lipoxygenase, C-terminal,domain-containing | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus granulosus | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Echinococcus multilocularis | arachidonate 5 lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Schistosoma mansoni | lipoxygenase | Get druggable targets OG5_127482 | All targets in OG5_127482 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1051 | 0.6356 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.1596 | 1 | 1 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.1596 | 1 | 1 |
Brugia malayi | thymidylate synthase | 0.0352 | 0.1686 | 0.1291 |
Brugia malayi | Dihydrofolate reductase | 0.1596 | 1 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0352 | 0.1686 | 0.1291 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.1051 | 0.6356 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0352 | 0.1686 | 0.1686 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.1051 | 0.6356 | 0.5 |
Echinococcus multilocularis | thymidylate synthase | 0.0352 | 0.1686 | 0.1441 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.1051 | 0.6356 | 0.5 |
Echinococcus granulosus | thymidylate synthase | 0.0352 | 0.1686 | 0.1441 |
Echinococcus multilocularis | dihydrofolate reductase | 0.1596 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.1596 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0167 | 0.0453 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.1596 | 1 | 1 |
Schistosoma mansoni | lipoxygenase | 0.0142 | 0.0286 | 0.0286 |
Chlamydia trachomatis | dihydrofolate reductase | 0.1596 | 1 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1051 | 0.6356 | 0.5 |
Onchocerca volvulus | 0.0352 | 0.1686 | 0.5 | |
Schistosoma mansoni | dihydrofolate reductase | 0.1596 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.1596 | 1 | 1 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.1051 | 0.6356 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.13 uM | Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line | ChEMBL. | 2104936 |
IC50 (binding) | = 0.13 uM | Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line | ChEMBL. | 2104936 |
IC50 (binding) | = 0.13 uM | Inhibition of 5-lipoxygenase in Rattus norvegicus Rat basophil leukemia cells (RBL) cells | ChEMBL. | No reference |
Inhibition (functional) | = 76 % | Percentage inhibition of the mouse arachidonic acid induced ear edema assay (AA) at a dose of 100 microg/ear | ChEMBL. | 2104936 |
Inhibition (functional) | = 76 % | Percentage inhibition of the mouse arachidonic acid induced ear edema assay (AA) at a dose of 100 microg/ear | ChEMBL. | 2104936 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.